FXYD3 and cancer: FXYD3 maintains the activity of the Na+/K+ pump to establish a decreased intracellular Ca2+ concentration and balanced redox status; this confers resistance to stressful conditions such as chemotherapy, since a pivotal consequence of chemotherapy, paclitaxel included, is ROS elevation, leading to cell death in numerous cancer types (57).